BRPI0512540A - composto de fórmula; método para o tratamento de um distúrbio do sistema nervoso central; composição farmacêutica; método para a determinação do metabolismo de um derivado de (1-arilsulfonil-1h-indol-3-il)etilamina; e uso do composto - Google Patents

composto de fórmula; método para o tratamento de um distúrbio do sistema nervoso central; composição farmacêutica; método para a determinação do metabolismo de um derivado de (1-arilsulfonil-1h-indol-3-il)etilamina; e uso do composto

Info

Publication number
BRPI0512540A
BRPI0512540A BRPI0512540-5A BRPI0512540A BRPI0512540A BR PI0512540 A BRPI0512540 A BR PI0512540A BR PI0512540 A BRPI0512540 A BR PI0512540A BR PI0512540 A BRPI0512540 A BR PI0512540A
Authority
BR
Brazil
Prior art keywords
compound
formula
indol
pharmaceutical composition
nervous system
Prior art date
Application number
BRPI0512540-5A
Other languages
English (en)
Inventor
Youchu Wang
Chia-Cheng Shaw
Ronald Charles Bernotas
Chung-Chiee Paul Wang
Ping Cai
Zhi Wang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35033547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512540(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0512540A publication Critical patent/BRPI0512540A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/033—Uronic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTO DE FóRMULA MéTODO PARA O TRATAMENTO DE UM DISTúRBIO DO SISTEMA NERVOSO CENTRAL; COMPOSIçãO FARMACêUTICA; MéTODO PARA A DETERMINAçãO DO METABOLISMO DE UM DERIVADO DE (l-ARILSULFONIL-lH-INDOL-3-IL) ETILAMINA; E USO DO COMPOSTO. A presente invenção proporciona um composto de fórmula I e o uso do mesmo para o tratamento terapêutico de disfunções relacionadas a ou afetadas pelo receptor 5-HT6.
BRPI0512540-5A 2004-06-23 2005-06-21 composto de fórmula; método para o tratamento de um distúrbio do sistema nervoso central; composição farmacêutica; método para a determinação do metabolismo de um derivado de (1-arilsulfonil-1h-indol-3-il)etilamina; e uso do composto BRPI0512540A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58229004P 2004-06-23 2004-06-23
PCT/US2005/021852 WO2006002125A1 (en) 2004-06-23 2005-06-21 Indolylalkylamine metabolites as 5-hydroxytrytamine-6 ligands

Publications (1)

Publication Number Publication Date
BRPI0512540A true BRPI0512540A (pt) 2008-03-25

Family

ID=35033547

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512540-5A BRPI0512540A (pt) 2004-06-23 2005-06-21 composto de fórmula; método para o tratamento de um distúrbio do sistema nervoso central; composição farmacêutica; método para a determinação do metabolismo de um derivado de (1-arilsulfonil-1h-indol-3-il)etilamina; e uso do composto

Country Status (19)

Country Link
US (1) US7498327B2 (pt)
EP (1) EP1758898A1 (pt)
JP (1) JP2008504267A (pt)
KR (1) KR20070041514A (pt)
CN (1) CN1976928A (pt)
AR (1) AR049449A1 (pt)
AU (1) AU2005258025A1 (pt)
BR (1) BRPI0512540A (pt)
CA (1) CA2570818A1 (pt)
CR (1) CR8825A (pt)
EC (1) ECSP067096A (pt)
IL (1) IL180198A0 (pt)
MX (1) MX2007000182A (pt)
NO (1) NO20070065L (pt)
PA (1) PA8637801A1 (pt)
PE (1) PE20060303A1 (pt)
RU (1) RU2006146923A (pt)
TW (1) TW200606148A (pt)
WO (1) WO2006002125A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101613B2 (en) 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489767A (en) * 1966-01-12 1970-01-13 Sumitomo Chemical Co 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
RU2309157C2 (ru) * 2001-12-20 2007-10-27 Уайт Производные индолилалкиламина в качестве лигандов 5-гидрокситриптамина-6
JPWO2004078719A1 (ja) * 2003-03-06 2006-06-08 小野薬品工業株式会社 インドール誘導体化合物およびその化合物を有効成分とする薬剤
NZ545326A (en) * 2003-07-17 2009-12-24 Plexxikon Inc PPAR active compounds
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity

Also Published As

Publication number Publication date
US20060003945A1 (en) 2006-01-05
JP2008504267A (ja) 2008-02-14
NO20070065L (no) 2007-01-04
EP1758898A1 (en) 2007-03-07
MX2007000182A (es) 2007-03-23
US7498327B2 (en) 2009-03-03
AR049449A1 (es) 2006-08-02
CA2570818A1 (en) 2006-01-05
ECSP067096A (es) 2007-02-28
KR20070041514A (ko) 2007-04-18
CN1976928A (zh) 2007-06-06
PA8637801A1 (es) 2006-06-02
TW200606148A (en) 2006-02-16
RU2006146923A (ru) 2008-07-27
WO2006002125A1 (en) 2006-01-05
PE20060303A1 (es) 2006-05-19
AU2005258025A1 (en) 2006-01-05
CR8825A (es) 2007-08-28
IL180198A0 (en) 2007-06-03

Similar Documents

Publication Publication Date Title
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
BR0312758A (pt) Derivados de 1-heterociclilalquil-3-sulfonilazaindol ou -azaindazol como ligantes da 5-hidroxitriptamina-6
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
UY28752A1 (es) Agentes terapeuticos
BRPI0607240A2 (pt) derivados de maleimida, composições farmacêuticas e métodos para tratamento de cáncer
BRPI0514005A (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal, e, processo para a preparação de um composto
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
UY28376A1 (es) Agentes terapéuticos
UY28374A1 (es) Agentes terapéuticos
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
CY1111603T1 (el) Παραγωγα benzimidazole και η χρηση τους για την τροποποιηση της συνθεσης ληπτη gabaa
BRPI0715746B8 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
BR9909597A (pt) Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.